The latest press releases, research breakthroughs, product launches, and company milestones from the world's fastest-growing AI-powered genomics company.
Gene Matrix celebrated the grand opening of its new global headquarters at Fulton Labs, 1375 W. Fulton St., Suite 545, Chicago — a 425,000 sq ft life-sciences tower purpose-built for AI-driven genomics and high-throughput molecular processing.
The official launch of GeneMatrix AI™ marks a milestone in precision medicine: 100 NVIDIA GPU processors, 1.5 petabytes of data capacity, and real-time CPIC guideline analysis delivering clinical-grade results with 99.5% accuracy — 10x faster than traditional methods.
Gene Matrix made its first major European move by launching GeneCancer™ hereditary cancer screening and GenePGx™ pharmacogenomics tests in Slovenia, partnering with Biotech Hills and Labena Group to train local clinicians in precision genomic care.
Gene Matrix announced a $50 million expansion into Wisconsin, Indiana, and Michigan, bringing AI-powered genetic testing closer to millions of patients across the Midwest. Negotiations with Walgreens and CVS are also underway to offer collection kits on retail shelves.
Gene Matrix completed full integration with Epic, Cerner, and Allscripts — the three largest EHR platforms in the US — enabling clinicians to order genetic tests and receive AI-interpreted results directly within their existing workflows.
In 2024, Gene Matrix crossed the 100,000-patient milestone, with tests processed across 37 hospital partners in 12 US states — a testament to the growing clinical demand for AI-powered precision medicine.
Gene Matrix announced the opening of its Series A funding round following a valuation of approximately $500 million. Proceeds will fuel global expansion, R&D acceleration, and the rollout of next-generation longevity and oncology recurrence prediction models.
The updated GenePGx™ panel now covers over 700 medications — the most comprehensive pharmacogenomics test on the market — using CPIC guidelines to prevent adverse drug reactions before symptoms begin, with real-time clinician dashboards.
Following its Slovenia launch, Gene Matrix rapidly expanded across the Balkans and into Azerbaijan, establishing local partnerships and clinician training programs to bring hereditary cancer screening and pharmacogenomics to underserved populations.
Gene Matrix confirmed Q1 2026 pilot programs with three of the most prestigious health systems in the world — Mayo Clinic, Cleveland Clinic, and Johns Hopkins — to validate GeneMatrix AI™ in high-volume clinical environments.
Gene Matrix Academy opened its doors in Chicago, offering structured training programs for healthcare providers on integrating precision genomic data into everyday patient care — a key pillar of the company's mission to democratize genetic medicine.
The GeneCancer™ 108-gene hereditary cancer panel sets a new standard for comprehensive risk screening, covering BRCA1/2, Lynch syndrome, and dozens of additional high-risk genes — all interpreted by the GeneMatrix AI™ engine with clinical-grade precision.
As Featured In
We use cookies to ensure our website functions securely and to improve your experience. As a healthcare provider handling sensitive genetic data, we adhere to strict HIPAA and GDPR standards. No personal health information (PHI) is ever stored in cookies. You can customize your preferences below.